Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat plus azacitidine versus placebo plus azacitidine in newly diagnosed acute myeloid leukemia
RBR-84s2ywPhase 3Recruiting
- Sponsor
- Helsinn
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Pracinostat + azacitidine with Placebo + azacitidine (2 arms). Started Oct 2018; status: recruiting.
02
Drugs
pracinostatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on RBR-84s2yw.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-84s2yw.